APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
Clinical trial NCT04260217 · COMPLETED
Trial details
- NCT number
- NCT04260217
- Sponsor
- Ascentage Pharma Group Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-30
- Primary completion
- 2024-02-05
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.